TYRA BIOSCIENCES INC (TYRA)
Health Care · biotechnology · NASDAQ
Tyra Biosciences is a clinical-stage biotech company using its proprietary SNAP platform to develop targeted small molecule inhibitors for FGFR-driven cancers and other diseases.
What TYRA BIOSCIENCES INC does
Tyra Biosciences is a clinical-stage biotechnology company focused on the development of precision medicines for oncology and conditions in fibroblast growth factor receptor (FGFR) biology. The company utilizes its proprietary in-house drug discovery platform, SNAP, to design small molecule inhibitors that target specific genomic drivers of disease.
Themes: precision medicine, oncology, drug discovery platform, FGFR inhibitors
Fundamentals
- Price$19.97 as of 2026-10-08 close
- Market cap$1.2B as of 2026-07-31 (share count; price 2026-10-08)
- 1-year return+46.5% 2025-10-08 close $13.63 → 2026-10-08 close $19.97
- P/En/a negative earnings
- ROE-46.3% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-02
- Beta0.95 as of 2026-09-02
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How TYRA compares in its sector
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How TYRA BIOSCIENCES INC looks technically
TYRA BIOSCIENCES INC (TYRA) is trading 34.3% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 33 trading days ago — a "death cross", a bearish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 35, neither overbought (above 70) nor oversold (below 30). It just made a new 20-day low, its first since 2025-11-19, breaking below its recent trading range. It is 50.9% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 34.3% below its 200-day average, the long-term trend line — a long-term downtrend | -34.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $25.04 | $25.04 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $30.41 | $30.41 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 17 calendar days ago — the swings before that are what the structure reading is measured on | 17 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 26.96. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 33 trading days ago — a "death cross", a bearish long-term signal | 33 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend) | 20.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 35, neither overbought (above 70) nor oversold (below 30) | 35.0 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($19.50 to $26.96) — its "stochastic" reading is 6 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 6.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 11 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $40.65 | $40.65 |
|---|---|---|
| From the 52-week high | it is 50.9% below its 52-week high (its highest price of the past year) | -50.9% |
| Above the 52-week low | it is 53.9% above its 52-week low (its lowest price of the past year) | +53.9% |
| Below the 52-week high | it is 50.9% below its highest point of the past year | 50.9% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2025-11-19, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day low, its first since 2025-11-19, breaking below its recent trading range | 1 session |
| All-time high | its highest closing price on record is $40.65 (set on 2026-04-01) | $40.65 |
| Given back of the 52-week move | over the past year its closes ranged ($13.37 to $39.61), and it has given back well over two thirds of its rise from last year’s low — 75% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $22.55 to $23.39. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 74.8% |
| From the all-time high | it is 50.9% below its all-time high | -50.9% |
| Nearest price level | it is trading 14.2% above a support level at $17.14 — a price it turned at twice since 2024-11-25, most recently on 2025-01-15. Since 2024-10-08 it has 8 such levels below the current price and 7 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -14.2% |
| All-time low | its lowest closing price on record is $5.02 (set on 2022-06-14) | $5.02 |
| Above the all-time low | it is 297.8% above its all-time low | +297.8% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 83% of the past ~6 months) | 83rd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.52 between its high and its low — about 7.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.52 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $18.71 and $26.68 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $18.71 – $22.70 – $26.68 |
| Typical daily range (% of price) | its price moves about 7.6% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.6% |
| Stretch from the 200-day average | it is trading 6.9 daily ranges below its 200-day average price (34.3% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.9 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.68× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a hammer | today, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | today |
|---|---|---|
| Since a bullish engulfing | 7 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 7 sessions ago |
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 1.3% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -1.3% |
|---|---|---|
| Open gap | it gapped 10.2% below the previous close 45 sessions ago and has not traded back through the level it left behind at 32.53 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -10.2% |
| Gap filled | a 5.3% gap up opened on 2026-09-14 has been "filled" 9 sessions ago — price traded back through the level the gap left behind, and it took 9 sessions to close | 9 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 26.3 percentage points (the stock lost 25.3% while the market gained 1.0%) | -26.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 42.5 percentage points (the stock lost 38.7% while the market gained 3.8%) | -42.5% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 66.2 percentage points (the stock lost 48.7% while the market gained 17.5%) | -66.2% |
| vs market, 12 months | over the past 12 months this stock beat the market by 31.5 percentage points (the stock gained 46.5% while the market gained 15.0%) | +31.5% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 26% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 8.9% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -26.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 35% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $30.65 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | -34.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 17% below the average price paid since it last reported on 2026-08-04 (its 10-Q), so the typical buyer over that stretch is under water. That average is $24.12 — a volume-weighted average of daily closes over 47 sessions, not a true tick-by-tick VWAP. | -17.2% |
Price levels it has turned at before
TYRA last closed at $19.97 on 2026-10-08. Since 2024-10-08 it has turned at 8 prices below its last close and 7 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $17.14 | Support | 14.2% below the last close | turned there twice · 2024-11-25 to 2025-01-15 |
| $24.11 | Resistance | 20.7% above the last close | turned there twice · 2025-12-11 to 2026-08-31 |
| $24.72 | Resistance | 23.8% above the last close | turned there three times · 2026-02-12 to 2026-08-14 |
| $14.97 | Support | 25.0% below the last close | turned there twice · 2024-11-15 to 2024-12-04 |
| $14.33 | Support | 28.2% below the last close | turned there twice · 2025-01-13 to 2025-10-01 |
| $27.10 | Resistance | 35.7% above the last close | turned there four times · 2026-01-20 to 2026-09-21 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $26.96.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $9.32 and $16.06 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $26.96.
This reading has stood for 9 trading days, since 2026-09-28.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · lagging the market · Printed a hammer candle after a decline · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.27 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$47.45 range $29.00 – $59.00; median $50.00
Analyst estimates, as of 2026-10-06. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for TYRA
- Consensus EPS estimate-$0.665 next reporting period, as of 2026-10-06
- Estimate change, 30 days+$0.01857 from -$0.6836, on 2026-09-01, 35-day window
- Readings revised upward25% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company has a history of operating losses and expects to incur significant additional losses as it advances its clinical pipeline.","The company's clinical development is heavily dependent on the success of its FGFR-targeted small molecule inhibitor programs, which face high risks of failure and regulatory hurdles.","The company may require significant additional capital to fund its research, development, and commercialization activities, which could lead to shareholder dilution."]
What changed in the latest 10-Q
AI-assisted comparison of TYRA's 10-Q filed 2026-05-13 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-13) references 'financial statements and notes thereto for the year ended December 31, 2025' and '2025 Annual Report' versus older filing's reference to December 31, 2024 and 2024 Annual Report
- Newer filing states SNÅP platform enables development of 'wholly-owned pipeline of oral small molecule product candidates'
- Newer filing specifies program indications as 'urothelial cancers and skeletal dysplasia conditions' with explicit mention that 'Alterations in the protein receptor FGFR3 are a validated driver in multiple indications'
- Newer filing states 'oral dabogratinib has been administered to over 100 participants across multiple clinical studies'
- Newer filing describes 'dabogratinib 3x3' strategy explicitly naming the approach
- Newer filing specifies SURF303 doses as '60 mg and 80 mg once daily'
- Newer filing states SURF302 has 'more than 20 patients enrolled at US and international trial sites'
- Newer filing states expectation to report 'initial three-month complete response data from both dose cohorts in August 2026' for SURF302
- Newer filing specifies BEACH301 enrollment as starting with 'sa' (text appears truncated)
- Removed:
- Older filing (2025-11-05) referenced pipeline products 'TYRA-430 and TYRA-200: three clinical-stage, novel small molecules' which are not mentioned in newer filing
- Older filing stated dabogratinib was 'formerly TYRA-300' nomenclature not included in newer filing
- Older filing described 'initial focus on Fibroblast Growth Factor Receptor (FGFR) biology' versus newer filing's 'harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology'
- Older filing described BEACH301 as having 'commenced enrolling a safety sentinel cohort planned for at least 3 participants per dose level' with 'dosed the first child in this study in August 2025' and interim results expected 'in the second half of 2026'
- Older filing stated SURF302 'will enroll up to 90 participants' and 'Following a review of efficacy and safety, an additional dosing cohort may be evaluated'
- Older filing stated SURF302 'dosed the first patient in this study in June 2025' and expected 'initial three-month CR data in the first half of 2026'
- Older filing stated SURF303 was 'recently expanded' and 'An investigational new drug application was cleared by the U.S. Food and Drug Administration in October 2025' with expectation to 'initiate this study in 2026'
- Older filing referenced ongoing SURF301 Phase 1/2 trial structure and design narrative
- Reworded:
- Older filing stated 'Mutations in the protein receptor FGFR3 are a key driver' changed to newer filing's 'Alterations in the protein receptor FGFR3 are a validated driver'
- Older filing used 'skeletal conditions and bladder cancer' language changed to newer filing's 'urothelial cancers and skeletal dysplasia conditions'
- Older filing described indications as 'pediatric achondroplasia (BEACH301), treatment of low-grade intermediate risk non-muscle invasive bladder cancer (SURF302), our recent expansion into the treatment of low-grade upper tract urothelial carcinoma (SURF303), and potentially for the treatment of metastatic urothelial carcinoma (SURF301)' versus newer filing's narrative describing SURF301 as already demonstrating 'initial clinical proof-of-concept results' with Phase 2 trials as current advancement
- Newer filing describes SURF303 as 'designed as a potential registrational trial' versus older filing stating it was 'recently expanded' with FDA clearance in October 2025
- Notes:
- Both filings appear truncated at the end of the BEACH301 and SURF301 sections, limiting complete comparison of those program descriptions
- The newer filing's text cuts off mid-sentence ('The study has enrolled the sa'), preventing full assessment of BEACH301 enrollment details
- Older filing's SURF301 description also cuts off mid-sentence ('was designed to determine the optimal an')
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
1 open-market purchase and 0 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-041 buy ($20000) · 0 sells — 1 buying insider
- Last 180 days · read to 2026-10-041 buy ($20000) · 0 sells — 1 buying insider
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-09. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about TYRA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding TYRA as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 14,649,467
- Reported value $467,903,976
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about TYRA's institutional holders → See what each manager we track holds →
Short interest (FINRA)
TYRA had 9,876,964 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
TYRA had 16.6% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.68 days to cover at the same settlement.
- Reported short interest (shares) 9,876,964
- Short interest (% of shares outstanding) 16.6%
- Prior settlement (shares) 9,440,216
- Reported change 4.63%
- Days to cover (reported) 5.68
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Blueprint Medicines (BPMC)
- Relay Therapeutics (RLAY)
- BridgeBio Pharma (BBIO)
- Incyte Corporation (INCY)
- Mirati Therapeutics (acquired by Bristol Myers Squibb)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare TYRA vs…
TYRA BIOSCIENCES INC is found in…
Frequently asked questions
What does TYRA BIOSCIENCES INC (TYRA) do?
Tyra Biosciences is a clinical-stage biotechnology company focused on the development of precision medicines for oncology and conditions in fibroblast growth factor receptor (FGFR) biology. The company utilizes its proprietary in-house drug discovery platform, SNAP, to design small molecule inhibitors that target specific genomic drivers of disease.
What sector is TYRA BIOSCIENCES INC (TYRA) in?
TYRA BIOSCIENCES INC (TYRA) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are TYRA BIOSCIENCES INC's (TYRA) competitors?
Notable peers of TYRA BIOSCIENCES INC (TYRA) include Blueprint Medicines, Relay Therapeutics, BridgeBio Pharma, Incyte Corporation and Mirati Therapeutics (acquired by Bristol Myers Squibb). This peer set is informational only — not financial advice.
Is TYRA BIOSCIENCES INC (TYRA) overbought or oversold right now?
TYRA BIOSCIENCES INC (TYRA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 35, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on TYRA come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.